title: Aztreonam activity in pneumology. Part 1: Clinical activity and pulmonary bioavailability of two different administration regimens.
abstract: Twenty-three patients suffering from lower respiratory tract infections caused by Gram-negative germs were treated with aztreonam (AZT) administered according to two different regimens: 17 subjects (Group A) with 2 g i.v. every 12 h and 6 patients (Group B) with 4 g in 100 ml of saline every 24 hours. Group A included 8 cases of superinfected bronchiectasis, 8 purulent bronchitis and 1 gangrene caused by Gram-negative and anaerobic agents. Group B comprised 6 patients with severe bronchiectasis infection. Pseudomonas aeruginosa was isolated from the sputum in 10/23 cases. The treatment was performed for 10 days on the average. The local and systemic tolerability was good. Group B, with higher antibiotic sputum concentrations for at least 12 hours, attained a better response than Group A: with clinical cure in 100% vs 76% cured plus 18% improved patients; therapy lasted 9.5 days for Group B vs 10.8 days for Group A. Moreover, in 14 subjects affected by pulmonary interstitial diseases who underwent diagnostic broncho-alveolar lavage, we dosed AZT in lavage fluids about 1 hour after the injection of a 2 g dose (Group C: 8 cases) or a 4 g dose (Group D: 6 cases). In group D antibiotic concentrations were significantly higher (P less than 0.005) than group C, while all the parameters that usually define the intensity of the alveolar alterations were not significantly different. Therefore, aztreonam administration in a daily monodose seems able to assure higher and longer lasting concentrations at the site of infection.
authors.affiliation: Division of Respiratory Diseases, University of Modena, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Velluti
authors.forename: O
authors.initials: O
authors.lastname: Capelli
authors.forename: M E
authors.initials: ME
authors.lastname: Bonucchi
authors.forename: A
authors.initials: A
authors.lastname: Calzati
authors.forename: M
authors.initials: M
authors.lastname: Lega
authors.forename: E
authors.initials: E
authors.lastname: Rovatti
authors.forename: F
authors.initials: F
authors.lastname: Gilioli
authors.forename: M
authors.initials: M
authors.lastname: Covi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001398:Aztreonam / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D001992:Bronchoalveolar Lavage Fluid / Q000378:metabolism; D004334:Drug Administration Schedule; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013183:Sputum / Q000378:metabolism
chemical_list: D001398:Aztreonam